Seftor REB - Search Results

1

CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1.

Shen L, Chen YL, Huang CC, Shyu YC, Seftor REB, Seftor EA, Hendrix MJC, Chien DS, Chu YW. Shen L, et al. Among authors: seftor reb. Pathol Oncol Res. 2023 Jun 7;29:1611038. doi: 10.3389/pore.2023.1611038. eCollection 2023. Pathol Oncol Res. 2023. PMID: 37351538 Free PMC article.

2

Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.

Hendrix MJ, Seftor EA, Seftor RE, Chao JT, Chien DS, Chu YW. Hendrix MJ, et al. Pharmacol Ther. 2016 Mar;159:83-92. doi: 10.1016/j.pharmthera.2016.01.006. Epub 2016 Jan 22. Pharmacol Ther. 2016. PMID: 26808163 Free PMC article. Review.

3

Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry.

Seftor RE, Seftor EA, Kirschmann DA, Hendrix MJ. Seftor RE, et al. Mol Cancer Ther. 2002 Nov;1(13):1173-9. Mol Cancer Ther. 2002. PMID: 12479698

4

Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry.

Hess AR, Seftor EA, Seftor RE, Hendrix MJ. Hess AR, et al. Cancer Res. 2003 Aug 15;63(16):4757-62. Cancer Res. 2003. PMID: 12941789

5

Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications.

Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ. Kirschmann DA, et al. Clin Cancer Res. 2012 May 15;18(10):2726-32. doi: 10.1158/1078-0432.CCR-11-3237. Epub 2012 Apr 2. Clin Cancer Res. 2012. PMID: 22474319 Free PMC article.

6

Heterogeneity of Melanoma with Stem Cell Properties.

Seftor EA, Margaryan NV, Seftor REB, Hendrix MJC. Seftor EA, et al. Among authors: seftor reb. Adv Exp Med Biol. 2019;1139:105-114. doi: 10.1007/978-3-030-14366-4_6. Adv Exp Med Biol. 2019. PMID: 31134497 Review.

7

Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry.

Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM Jr, Cohen MB, Lubaroff DM, Hendrix MJ. Sharma N, et al. Prostate. 2002 Feb 15;50(3):189-201. doi: 10.1002/pros.10048. Prostate. 2002. PMID: 11813211

8

Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry.

Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, Kirschmann DA, Seftor RE, Hendrix MJ. Seftor EA, et al. Crit Rev Oncol Hematol. 2002 Oct;44(1):17-27. doi: 10.1016/s1040-8428(01)00199-8. Crit Rev Oncol Hematol. 2002. PMID: 12398997 Review.

9

Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma.

Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Hendrix MJ, et al. Nat Rev Cancer. 2003 Jun;3(6):411-21. doi: 10.1038/nrc1092. Nat Rev Cancer. 2003. PMID: 12778131 Review.

10

VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry.

Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ. Hess AR, et al. Cancer Biol Ther. 2006 Feb;5(2):228-33. doi: 10.4161/cbt.5.2.2510. Epub 2006 Feb 14. Cancer Biol Ther. 2006. PMID: 16481735 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters